QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 athira-pharma-has-been-granted-a-us-patent-methods-of-treating-neurodegenerative-disease-including-dementia-alzheimers-disease-and-parkinsons-disease-with-substituted-n-hexanoic-l-tyrosine-l-isoleucine-6-aminohexanoic-amide-analogues-httpstconshlvnfwcm

https://ppubs.uspto.gov/pubwebapp/external.html?q=(12421276).pn

 athira-pharma-to-implement-10-for-1-reverse-stock-split-following-shareholder-approval-at-may-2025-annual-meeting

Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused o...

 athira-pharma-q2-eps-018-inline

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a ...

 athira-pharma-to-present-data-from-phase-1-clinical-trial-of-ath-1105-in-healthy-volunteers-at-4th-annual-als-drug-development-summit

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose pro...

 athira-pharma-q1-eps-023-up-from-069-yoy

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.23) per share. This is a 66.67 percent increase over losses of $(0...

 athira-pharma-fy-2024-gaap-eps-252-beats-254-estimate

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(2.52) per share which beat the analyst consensus estimate of $(2.54)...

 athira-pharma-presents-preclinical-data-highlighting-neuroprotective-effects-of-ath-1105-in-models-of-als-at-motor-neurone-disease-associations-international-symposium-on-alsmnd

Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore ...

 athira-pharma-q3-eps-075-misses-069-estimate

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.6...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION